Phase II study of neoadjuvant treatment with doxorubicin, docetaxel, and capecitabine (ATX) in locally advanced or inflammatory breast cancer
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Pathologic complete response (pCR) after preoperative systemic chemotherapy (PSCh) is associated with better outcome in locally advanced breast cancer (LABC).
Patients and methods
PSCh included: doxorubicin (A) 50 mg/m2 i.v. on day 1; docetaxel (T) 30 mg/m2 i.v. on days 1, 8 and 15; and capecitabine (X) 1,500 mg/m2/day p.o. on days 1–14, in a 4-week course repeated for up to four cycles (ATX), followed by surgery. The primary end point of this study was to evaluate the pCR rate. Secondary endpoints included clinical response rate, disease-free survival (DFS), overall survival (OS), and the toxicity profile.
A total of 60 patients were included in the analysis. Median age was 49 years, and 63.3% of patients were hormone receptor positive. The median number of cycles of PSCh was four (95% CI: 3–4). Five patients (8.3%) achieved pCR in both breast and nodes, and 16.7% reached pCR only in nodes. The clinical response rate was 77% (27% complete response), but only 18% of the patients underwent conservative surgery. With a median follow-up of 20 months, 3-year DFS and OS were 76 and 90%, respectively. Grade III/IV toxicity included neutropenia (74%), febrile neutropenia (9%), mucositis (12%), and diarrhea (12%).
ATX every 28 days for four cycles is associated with a modest activity (low pCR rate) in the neoadjuvant setting of LABC.
- Fisher B, Brown A, Mamounas EP, Wieand S, Robidoux A, Margolese RG, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from national surgical adjuvant breast and bowel project B18. J Clin Oncol. 1997;15:2483–93.
- Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol. 2006;24:1940–9. CrossRef
- Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005;97:188–94. CrossRef
- Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol. 2006;24:1037–44. CrossRef
- Smoot RL, Koch CA, Degnim AC, Sterioff S, Donohue JH, Grant CS, et al. A single-center experience with inflammatory breast cancer, 1985–2003. Arch Surg. 2006;141:567–72. CrossRef
- Han S, Kim SB, Kang SS, Noh WC, Paik NS, Chang ES, et al. A phase II study of neoadjuvant docetaxel plus doxorubicin (KBCS-01) in stage II, III breast cancer. Breast Cancer Res Treat. 2006;98:57–61. CrossRef
- Quiben R, Palomero MI, Cassinello J, Pérez-Manga G. Doxorubicin combined with weekly docetaxel in locally advanced or inflammatory breast cancer (BC). Goti Study Group Proc Am Soc Clin Oncol. 2001;37:1901. (abstr 1901).
- Layman RM, Thomas DG, Griffith KA, Smerage JB, Helvie MA, Roubidoux MA, et al. Neoadjuvant docetaxel and capecitabine and the use of thymidine phosphorylase as a predictive biomarker in breast cancer. Clin Cancer Res. 2007;13:4092–7. CrossRef
- Tagaya N, Nakagawa A, Mori S, Hamada K, Suzuki N, Kubota K. Pilot study of primary systemic chemotherapy with docetaxel (DOC), epirubicin (EPI) and capecitabine (Xeloda) in patients with advanced breast cancer. Gan To Kagaku Ryoho. 2006;33:39–42.
- Venturini M, Del Mastro L, Garrone O, Angiolini C, Merlano M, Bergaglio M, et al. Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer. Ann Oncol. 2002;13:546–52. CrossRef
- Sachelarie I, Grossbard ML, Chadha M, Feldman S, Ghesani M, Blum RH. Primary systemic therapy of breast cancer. Oncologist. 2006;11:574–89. CrossRef
- Makris A, Powles TJ, Ashley SE, Chang J, Hickish T, Tidy VA, et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol. 1998;9:1179–84. CrossRef
- Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26:778–85. CrossRef
- Gianni L, Baselga L, Eiermann W, Guillem Porta V, Semiglazov V, Lluch A, et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res. 2005;11:8715–21. CrossRef
- Bear HD, Anderson S, Smith RE, Geyer CE, Mamounas EP, Fisher B, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project protocol B-27. J Clin Oncol. 2006;24:2019–27. CrossRef
- Colleoni M, Viale G, Zahrieh D, Pruneri G, Gentilini O, Veronesi P, et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res. 2004;10:6622–8. CrossRef
- Ring AE, Smith IE, Ashley S, Fulford LG, Lakhani SR. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer. 2004;91:2012–7. CrossRef
- von Minckwitz G, Raab G, Caputo A, Schütte M, Hilfrich J, Blohmer JU, et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol. 2005;23:2676–85. CrossRef
- Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol. 2005;23:5983–92. CrossRef
- Heys SD, Hutcheon AW, Sarkar TK. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer. 2002;3:S69–74. CrossRef
- Khosravi P, Pérez-Manga G. La relevancia clínica de la sobreexpresión de HER-2 en el cáncer de mama. An Med Int. 2006;23:103–4.
- Wenzel C, Hussian D, Bartsch R, Pluschnig U, Locker GJ, Rudas M, et al. Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: a pilot study. J Cancer Res Clin Oncol. 2004;30:400–4.
- Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005;23:3676–85. CrossRef
- Rivera E, Mejia JA, Arun BK, Adinin RB, Walters RS, Brewster A, et al. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer. 2008;112:1455–61. CrossRef
- Phase II study of neoadjuvant treatment with doxorubicin, docetaxel, and capecitabine (ATX) in locally advanced or inflammatory breast cancer
Volume 17, Issue 3 , pp 205-211
- Cover Date
- Print ISSN
- Online ISSN
- Springer Japan
- Additional Links
- Preoperative chemotherapy
- Industry Sectors
- Author Affiliations
- 1. Servicio de Oncología Médica, Hospital General Universitario “Gregorio Marañón”, C/Maiquez, 7, 28007, Madrid, Spain
- 2. Servicio de Oncología Médica, Hospital de Mostoles, Madrid, Spain
- 3. Servicio de Oncología Médica, Hospital Virgen de las Nieves, Granada, Spain